Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Silver Range Resources: A hidden gem in the mining industry (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Allovir Inc ALVR

Healthcare Biotechnology
AlloVir, Inc. is an allogeneic T cell immunotherapy company with a focus on restoring natural immunity against life-threatening viral diseases in pediatric and adult patients with weakened immune systems. The company’s proprietary technology platforms leverage off-the-shelf, allogeneic, single- and multi-virus-specific T cells for patients with T cell deficiencies who are at risk from the life... see more

Recent & Breaking News (NDAQ:ALVR)

AlloVir Reports First Quarter 2022 Financial Results

Business Wire May 5, 2022

FDA Grants Regenerative Medicine Advanced Therapy (RMAT) Designation to AlloVir's Posoleucel for Prevention of Multiple Life-Threatening Infections from Six Viruses in Allogeneic Hematopoietic Cell Transplant Patients

Business Wire April 20, 2022

AlloVir Appoints Shawn Tomasello to Its Board of Directors

Business Wire March 31, 2022

AlloVir Initiates Global Phase 3 Registrational Study of Posoleucel for Prevention of Life-Threatening Viral Infections from Six Common Viruses in High-Risk, Allogeneic Hematopoietic Cell Transplant Patients

Business Wire March 22, 2022

AlloVir to Participate in the 11th Annual SVB Leerink Global Healthcare Conference

Business Wire February 11, 2022

AlloVir Reports Full-Year 2021 Financial Results and 2022 Outlook

Business Wire February 10, 2022

FDA Grants Regenerative Medicine Advanced Therapy (RMAT) Designation to AlloVir's Posoleucel for the Treatment of Adenovirus (AdV) Infections in Adults and Children Post-Allogeneic Stem Cell Transplantation

Business Wire January 5, 2022

AlloVir to Present at the 40th Annual J.P. Morgan Healthcare Conference

Business Wire January 3, 2022

AlloVir Announces Departure of Chief Medical Officer Augustin Melian

Business Wire December 16, 2021

AlloVir Announces Positive Preliminary Data from the Ongoing Phase 2 Posoleucel Multi-Virus Prevention Study at the 63rd American Society of Hematology Annual Meeting

Business Wire December 11, 2021

AlloVir to Participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference

Business Wire November 15, 2021

AlloVir Reports Third Quarter 2021 Financial Results

Business Wire November 5, 2021

FDA Grants Orphan Drug Designation (ODD) to AlloVir's Posoleucel, an Allogeneic, Off-the-Shelf, Multi-Virus Specific T-Cell Therapy, for the Treatment of Virus-Associated Hemorrhagic Cystitis

Business Wire October 4, 2021

Data Presented at IDWeek(TM) 2021 Demonstrate that ALVR109, AlloVir's Investigational SARS-CoV-2-Specific T Cell Therapy, Is Reactive Against a Broad Range of Variants, Including Delta

Business Wire September 29, 2021

AlloVir to Present at the Morgan Stanley 19th Annual Global Healthcare Conference

Business Wire September 7, 2021

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Avalara, Inc. - ALVR

Newsfile August 26, 2021

AlloVir Reports Second Quarter 2021 Financial Results

Business Wire August 6, 2021

AlloVir Reports First Quarter 2021 Financial Results

Business Wire May 6, 2021

AlloVir Appoints Diana M. Brainard, M.D., as Chief Executive Officer, Effective May 17, 2021

Business Wire March 22, 2021

AlloVir to Present at the 10th Annual SVB Leerink Global Healthcare Conference

Business Wire February 17, 2021